Trial
NCT00886769
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Southwest Pediatric Nephrology Study Group
Condition
Systemic Juvenile Idiopathic Arthritis
Intervention
Canakinumab
Why stopped
recommendation by Data Monitoring Committee
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-29